Linked to numerous age-associated conditions of chronic inflammation [19–22] and multiple complications of diabetes [23–27], an intervention which selectively blocks NLRP3 inflammasome activation in a sterile setting would undoubtedly maximise positive patient outcomes and potentially lessen reliance on polypharmacy [28]. The gene discussed is NLRP3; the disease is diabetes mellitus.